Skip to main content

Table 6 Recommendation summary – Monitoring recommendations for patients with established CKD

From: Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines

  CEBAM ACP HAS KDIGO KHA-CARI BCMA UMHS VA-DoD NICE
2012 2013 2013 2013 2013 2014 2014 2014 2015
Monitoring patients with known CKD
frequency (times /year)
 G1/A1 1    1   1 1   ≤1
 G1/A2 1    1   1 1   1
 G1/A3 1    2   2 2   ≥1
 G2/A1 1    1   1 1   ≤1
 G2/A2 1    1   1 1   1
 G2/A3 2    2   2 2   ≥1
 G3a/A1 2    1   1 1   1
 G3a/A2 2    2   2 2   1
 G3a/A3 2    3   3 3   2
 G3b/A1 2    2   2 2   ≤2
 G3b/A2 2    3   3 3   2
 G3b/A3 ≥4    3   3 3   ≥2
 G4/A1 ≥4    3   3 4**   2
 G4/A2 ≥4    3   3 3   2
 G4/A3 ≥4    ≥4   ≥4 ≥4   3
 G5/A1 ≥4    ≥4   ≥4 ≥4   4
 G5/A2 ≥4    ≥4   ≥4 ≥4   ≥4
 G5/A3 ≥4    ≥4   ≥4 ≥4   ≥4
parameter
 blood pressure * *   *   *
 weight         
 (e)GFR   
 albuminuria/proteinuria/ACR   
 complete blood count         
 iron saturation         
 HbA1c         
 serum calcium         
 serum phosphorus         
 serum potassium       i i   
 serum albumin         
 complications         
 inulin          i
 51Cr-EDTA          i
 125I-iothalamate          i
 iohexol          i
 cardiovascular risk      ▪➢    
 smoking status         
 medication        
 psychosocial health         
  1. ▪ recommendation, − negative recommendation, i: when indicated, *not specifically mentioned, but obvious from the context (e.g. blood pressure targets), **probably transcription error, ➢ refers to British Columbian guideline “Cardiovascular disease - primary prevention”
  2. Stages of CKD: G1, glomerular filtration rate of ≥90 ml/min/1.73m2; G2, 60–89 ml/min/1.73m2; G3a, 45–59 ml/min/1.73m2; G3b, 30–44 ml/min/1.73m2; G4, 15–29 ml/min/1.73m2; G5, < 15 ml/min/1.73m2
  3. Albuminuria stages of CKD: A1, albumine-creatinine-ratio < 3 mg/mmol; A2, 3–30 mg/mmol; A3, > 30 mg/mmol
  4. ACR albumin-creatinine-ratio, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, 51Cr-EDTA chromium-51-ethylenediaminetetraacetic acid
  5. American College of Physicians (ACP), Belgisch Centrum voor Evidence Based Medicine (CEBAM), British Columbia Medical Association (BCMA), Department of Veteran’s Affairs (VA-DoD), Haute Autorité de Santé (HAS), Kidney Disease Improving Global Outcomes (KDIGO), Kidney Health Australia - Caring for Australasiansians with Renal Impairment (KHA-CARI), National Institute of Health and Care Excellence (NICE), University of Michigan Health System (UMHS)